Comparison
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980 vs 14q11 2 Microduplication Syndrome C4749855
Clinical comparison between 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete CN042980 and 14q11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
A rare enzyme deficiency affecting hormone production, leading to low sex hormones and elevated blood pressure. Lifelong hormone replacement therapy is typically needed. Ongoing medical monitoring helps manage associated health concerns.
14q11 2 Microduplication Syndrome C4749855
A rare genetic condition involving a small extra piece of chromosome 14. Features vary and may include developmental delays. Management focuses on supportive therapies and monitoring.
6 comparison axes
Onset
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
0-null
14q11 2 Microduplication Syndrome C4749855
0-5
Onset patterns differ
Severity
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
severe
14q11 2 Microduplication Syndrome C4749855
moderate
Different severity levels
Chronic
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
Chronic
14q11 2 Microduplication Syndrome C4749855
Chronic
Differing course
Communicable
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
No
14q11 2 Microduplication Syndrome C4749855
No
Different transmission
Body System
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
endocrine
14q11 2 Microduplication Syndrome C4749855
congenital
Same/different system
Category
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
endocrine
14q11 2 Microduplication Syndrome C4749855
genetic
Different category
Bottom line
17-alpha-hydroxylase-17-20-lyase-deficiency-combined-complete-CN042980 and 14q11-2-microduplication-syndrome-C4749855 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980 | 14q11 2 Microduplication Syndrome C4749855 | Discriminating power |
|---|---|---|---|
| Blood pressure | Hypertension is a recognized feature of mineralocorticoid excess. | Hypertension is not an established core feature. | High |
| Sex development | Low sex-hormone production may cause atypical puberty or genital development. | Sex-hormone deficiency is not the defining feature. | High |
| Development | Developmental delay is not the primary described manifestation. | Features vary and may include developmental delay. | Moderate |
When to favor each condition
Choose 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980 when
Hypertension with suspected sex-hormone deficiency
This pattern fits the described endocrine enzyme deficiency better than a chromosomal duplication.
Moderate
Need for lifelong hormone replacement
Replacement is typically described for the enzyme deficiency, not the microduplication.
Moderate
Endocrine rather than developmental presentation
The supplied category is endocrine and severity is severe.
Moderate
Choose 14q11 2 Microduplication Syndrome C4749855 when
Early childhood developmental concerns
Onset is listed as 0-5 years and developmental delay may occur.
Moderate
Suspected chromosomal copy-number change
The condition is defined by a small extra segment of chromosome 14.
High
Variable congenital features without endocrine diagnosis
Management is supportive and features are variable.
Moderate
How key tests differ
| Test | 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980 | 14q11 2 Microduplication Syndrome C4749855 | Interpretation |
|---|---|---|---|
| Steroid hormone profile | Abnormal sex-steroid and mineralocorticoid-related pattern may be expected. | No specific steroid abnormality is established. | An abnormal profile supports endocrine evaluation but is not itself a diagnosis. |
| Chromosomal microarray | Not the defining test for this enzyme deficiency. | May identify the 14q11.2 microduplication. | Genetic confirmation requires specialist interpretation of clinical relevance. |
| Blood pressure monitoring | Hypertension may be detected and needs follow-up. | No characteristic blood-pressure finding is established. | Measurement guides care but does not distinguish diagnoses alone. |
Prognosis comparison
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
- Outcome
- Severe chronic endocrine condition; exact survival or complication rates are not established here.
- Factors
- Blood-pressure control, hormone replacement, and specialist monitoring.
14q11 2 Microduplication Syndrome C4749855
- Outcome
- Moderate chronic condition with variable developmental impact; precise prognosis is not established.
- Factors
- Extent of features, developmental support, and associated findings.
Time frame: Lifelong monitoring is generally relevant; exact timelines are not established.
Diagnosis confirmation, associated complications, and access to specialist care.
Complications comparison
| Complication | Presentation |
|---|---|
| Hypertension-related harm | Elevated blood pressure is a recognized concern. Not established as a characteristic complication. Exact risks and outcomes are not supplied. |
| Hormone deficiency effects | Low sex hormones may affect puberty, fertility, and bone health. Not described as the primary complication. Individual effects require endocrine assessment. |
| Developmental impairment | Not established as a core complication. Developmental delay may occur, with variable severity. Support needs depend on the individual profile. |
Patient education highlights
- HighDifferent causes
One is a hormone-production enzyme deficiency; the other is a chromosomal duplication.
- HighFollow-up
Both are chronic and need individualized monitoring; neither is communicable.
- MediumTreatment approach
Hormone replacement is typical for the enzyme deficiency, while supportive therapies are central for the microduplication.